Alto Neuroscience, a California-based biotech company, is making strides in depression therapy using artificial intelligence (AI) to match patients with drugs based on brain biomarkers. In a phase 2a clinical trial, their approach has shown promise in improving the treatment outcomes for patients with major depressive disorder (MDD) who do not respond well to their ... Read more